SCARLETRED

Executive Summary

SCARLETRED is a Boston-based digital health company revolutionizing dermatology through standardization and objectivity in skin imaging and assessment. Its flagship product, Scarletred®Vision, is a mobile medical device system that enables consistent, high-quality skin imaging, addressing a critical gap in dermatological diagnosis where subjective visual assessment often leads to variability. Founded in 2016, the company operates in the rapidly growing teledermatology and digital pathology markets, leveraging smartphone technology combined with proprietary algorithms to enhance diagnostic accuracy and expand access to dermatological care, particularly in underserved areas. While SCARLETRED remains in a relatively early stage, its focus on mobile, objective skin imaging aligns with the broader telehealth trend and growing demand for remote dermatology solutions. The company has yet to disclose funding rounds or regulatory clearances, but its technology holds promise for integration into clinical workflows, direct-to-consumer services, and partnerships with healthcare systems. If successful, SCARLETRED could become a key enabler of standardized skin assessment, improving outcomes and efficiency in dermatology. However, execution risks and competitive pressures from established players necessitate cautious optimism.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Scarletred®Vision50% success
• H2 2026Strategic Partnership with a Major Telehealth Provider40% success
• Q3 2026Institutional Series A Funding Round60% success